Intriguingly, several large cardiovascular outcome trials including the EMPA-REG-OUTCOME, CANVAS Program, and DECLARE-TIMI 58 found that SGLT2 inhibitors lower cardiovascular disease and/or mortality relative to other anti-glycemic agents in patients with T2DM [15,16,17]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.